Synthetic Biologics has entered into an agreement with Prev AbR to acquire its clinical-stage and related beta-lactamase assets for the prevention of Clostridium difficile (C. diff) infection, the leading cause of hospital acquired infections (HAI), which may occur secondary to treatment with antibiotics. The assets include a pre-IND package, Phase I and II data, manufacturing process data, and all patents to support an IND and BLA with the FDA.   Synthetic Biologics plans to develop and commerc...